Tuesday, Medtronic Plc (NYSE:MDT) reported third-quarter 2024 sales of $8.1 billion, up 4.7% year-on-year (Y/Y) as reported and 4.6% organic, slightly beating the consensus of $7.95 billion.
“Our recent major product approvals – including transformative products in diabetes, cardiac rhythm management, neuromodulation, hypertension, and pulsed-field ablation spaces – increase our confidence in driving reliable growth over the coming quarters and years,” said Geoff Martha, Medtronic chairman, and CEO.
The adjusted EPS of $1.30 exceeds the consensus of $1.26.
Medtronic’s heart device unit sales increased 6.1% Y/Y …
Leave a Reply